

9 November 2005

Dear Consultee/Commentator

Health Technology Appraisal

Irinotecan for the adjuvant treatment of colon cancer

As you maybe aware, the Department of Health and the Welsh Assembly Government asked the Institute to conduct an appraisal of irinotecan for the adjuvant treatment of colon cancer, and to provide guidance on its use to the NHS in England and Wales.

Irinotecan is not currently licensed in the UK for this indication. After discussion with the manufacturer the Institute has decided to suspend this appraisal at this time.

We intend to set the timelines of the appraisal to coincide with the licensing process, and will provide detailed appraisal timelines when more precise information on expected licensing dates becomes available.

I hope you understand that this action has been taken to ensure the appraisal proceeds smoothly. However, if you have any comments or concerns please do not hesitate to contact the Project Manager for this appraisal, Cathryn Fuller (☎ 020 7067 5896 or email: Cathryn.fuller@nice.org.uk).

Yours sincerely

Dr Carole Longson
Director of Centre for Health Technology Evaluation